About Stromelysin-3
Stromelysin-3 (MMP11) is a protein
from Homo sapiens identified by UniProt accession
P24347, 488 residues long.
MolForge cross-references it against 0 known binders and
267 disease associations.
Target properties
| Protein name | Stromelysin-3 |
| UniProt accession | P24347 |
| Gene | MMP11 |
| Organism | Homo sapiens |
| Length | 488 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (267)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.42
- ulcerative colitis · score 0.26
- lung adenocarcinoma · score 0.25
- breast adenocarcinoma · score 0.23
- serum IgG glycosylation measurement · score 0.17
- cutaneous melanoma · score 0.15
- creatinine measurement · score 0.15
- left ventricular systolic function measurement · score 0.11
- ejection fraction measurement · score 0.11
- neoplasm · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P24347-F1 | alphafold | PREDICTED | 77.21 | — |
Amino-acid sequence (488 residues)
MAPAAWLRSA AARALLPPML LLLLQPPPLL ARALPPDAHH LHAERRGPQP WHAALPSSPA PAPATQEAPR PASSLRPPRC GVPDPSDGLS ARNRQKRFVL SGGRWEKTDL TYRILRFPWQ LVQEQVRQTM AEALKVWSDV TPLTFTEVHE GRADIMIDFA RYWHGDDLPF DGPGGILAHA FFPKTHREGD VHFDYDETWT IGDDQGTDLL QVAAHEFGHV LGLQHTTAAK ALMSAFYTFR YPLSLSPDDC RGVQHLYGQP WPTVTSRTPA LGPQAGIDTN EIAPLEPDAP PDACEASFDA VSTIRGELFF FKAGFVWRLR GGQLQPGYPA LASRHWQGLP SPVDAAFEDA QGHIWFFQGA QYWVYDGEKP VLGPAPLTEL GLVRFPVHAA LVWGPEKNKI YFFRGRDYWR FHPSTRRVDS PVPRRATDWR GVPSEIDAAF QDADGYAYFL RGRLYWKFDP VKVKALEGFP RLVGPDFFGC AEPANTFL
Explore Stromelysin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets